Idun the Latest to Seek Shelter via Pfizer's M&A Highway
This article was originally published in Start Up
Executive Summary
In February, Idun Pharmaceuticals became the fourth company acquired by Pfizer in the last 15 months. While those transactions reflect different mixes of product and technology breadth, they suggest a greater alignment between the interests of some private biotechs, their investors, and potential pharma company acquirers, as well as an evolution in the deal calculus for choosing M&A over an alliance or IPO.
You may also be interested in...
Roche Opens NY R&D Hub As Its pRED Head Vows To Boost Alliances
Amid a day of celebrations around the long-awaited opening of its translational and clinical research center in New York, Roche’s new head of research and early development, the superstar scientist John Reed, offered a glimpse of how the organization is restructuring its external relationships and its priorities going forward.
UCSF Spinout Calithera Biosciences Takes $40 Million First Round
The cancer-fighting drug researcher is developing methods of activating caspases, enzymes that induce programmed cell death.
UCSF Spinout Calithera Biosciences Takes $40 Million First Round
The cancer-fighting drug researcher is developing methods of activating caspases, enzymes that induce programmed cell death.